ASDS News: CellFX Clears Low-Risk Basal Cell Carcinoma Lesions

October 6, 2022
ASDS News CellFX Clears LowRisk Basal Cell Carcinoma Lesions image

Excisional surgery using electrodesiccation and curettage (ED&C) or Mohs micrographic surgery are the current standards of care for BCC lesions, both of which inevitably lead to scarring.

CellFX procedure is effective for low-risk superficial and nodular basal cell carcinoma lesion clearance, according to research presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting.

"It is exciting and encouraging to see complete clearance of basal cell carcinoma lesions using Nano-Pulse Stimulation (NPS) technology," says Amy Ross, MD, medical director and founder of PHDermatology of Tampa, Florida, and study investigator, in a news release. NPS technology delivers nanosecond pulses of electrical energy directed to the cellular component of the lesion to non-thermally clear damaged cells while sparing the surrounding healthy collagen-rich tissue. "The results shown in this study gives me a high degree of confidence in NPS technology as an effective and cosmetically acceptable treatment, and potential alternative to the current standard of care for these types of BCC lesions."

Excisional surgery using electrodesiccation and curettage (ED&C) or Mohs micrographic surgery are the current standards of care for BCC lesions, both of which inevitably lead to scarring.

"Showcasing this exciting new clinical data to dermatology thought leaders at ASDS is a major step towards demonstrating the applicability of NPS technology beyond benign dermatologic conditions," says Kevin Danahy, President and Chief Executive Officer of Pulse Biosciences. "The ongoing body of clinical evidence in dermatology continues to prove that NPS technology is safe and effective and produces excellent outcomes."

Facebook Comments

Register

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free